Zhejiang Huahai Pharmaceutical Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Zhejiang Huahai Pharmaceutical kazanç ve gelirin sırasıyla yıllık 22% ve 15.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 22% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 17.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

22.0%

Kazanç büyüme oranı

22.0%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	19.0%
Gelir büyüme oranı	15.5%
Gelecekteki özkaynak getirisi	17.4%
Analist kapsamı	Low
Son güncelleme	31 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Investors Holding Back On Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521)

Oct 22

Here's Why Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Meaningful Debt Burden

Sep 25

Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 20

Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt

May 28

There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings

May 06

Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel

Mar 22

Kazanç ve Gelir Büyüme Tahminleri

SHSE:600521 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	13,220	1,897	N/A	3,650	2
12/31/2025	11,717	1,624	N/A	1,067	3
12/31/2024	9,985	1,324	N/A	1,941	3
9/30/2024	9,349	1,140	1,171	2,643	N/A
6/30/2024	9,143	1,010	1,173	2,624	N/A
3/31/2024	8,748	928	1,139	2,696	N/A
12/31/2023	8,309	830	625	2,217	N/A
9/30/2023	8,635	1,095	116	2,096	N/A
6/30/2023	8,736	1,169	-531	1,643	N/A
3/31/2023	8,552	1,203	-772	1,515	N/A
12/31/2022	8,266	1,168	-1,074	1,243	N/A
9/30/2022	7,884	692	-1,482	857	N/A
6/30/2022	7,432	540	-1,648	1,015	N/A
3/31/2022	6,919	370	-1,514	975	N/A
12/31/2021	6,644	488	-1,496	938	N/A
9/30/2021	6,212	679	-994	1,068	N/A
6/30/2021	6,215	867	-285	1,341	N/A
3/31/2021	6,412	964	-282	1,265	N/A
12/31/2020	6,485	930	279	1,555	N/A
9/30/2020	6,247	898	546	1,670	N/A
6/30/2020	6,041	813	858	1,774	N/A
3/31/2020	5,760	655	1,054	1,877	N/A
12/31/2019	5,388	570	960	1,754	N/A
9/30/2019	5,263	364	391	1,340	N/A
6/30/2019	5,209	213	-280	740	N/A
3/31/2019	5,055	81	-538	560	N/A
12/31/2018	5,095	108	-1,057	68	N/A
9/30/2018	5,335	409	-630	506	N/A
6/30/2018	5,190	573	N/A	644	N/A
3/31/2018	5,112	661	N/A	518	N/A
12/31/2017	5,002	639	N/A	646	N/A
9/30/2017	4,680	601	N/A	222	N/A
6/30/2017	4,460	537	N/A	231	N/A
3/31/2017	4,254	519	N/A	306	N/A
12/31/2016	4,093	501	N/A	433	N/A
9/30/2016	4,001	492	N/A	453	N/A
6/30/2016	3,848	466	N/A	325	N/A
3/31/2016	3,738	464	N/A	238	N/A
12/31/2015	3,500	442	N/A	195	N/A
9/30/2015	3,201	399	N/A	262	N/A
6/30/2015	3,071	372	N/A	262	N/A
3/31/2015	2,793	313	N/A	258	N/A
12/31/2014	2,585	266	N/A	329	N/A
9/30/2014	2,406	277	N/A	217	N/A
6/30/2014	2,220	265	N/A	419	N/A
3/31/2014	2,224	310	N/A	433	N/A
12/31/2013	2,296	359	N/A	490	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 600521 'nin tahmini kazanç büyümesi (yıllık 22% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 600521 şirketinin kazançlarının (yıllık 22% ) CN pazarından (yıllık 26.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 600521 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: 600521 şirketinin gelirinin (yıllık 15.5% ) CN pazarından (yıllık 13.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 600521 şirketinin gelirinin (yıllık 15.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 600521 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 17.4 %).

Zhejiang Huahai Pharmaceutical Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates increase by 14%

Price target increased by 11% to CN¥18.17

Consensus revenue estimates fall by 10%

Price target decreased by 11% to CN¥17.60

Consensus EPS estimates fall by 13%

Price target decreased by 10% to CN¥20.63

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.11 in 3Q 2023)

Investors Holding Back On Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521)

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 25%

Here's Why Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Meaningful Debt Burden

Second quarter 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.27 in 2Q 2023)

Consensus EPS estimates increase by 14%

Dividend reduced to CN¥0.20

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price

Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt

There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings

Price target increased by 11% to CN¥18.17

Zhejiang Huahai Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

First quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.12 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥0.57 (vs CN¥0.81 in FY 2022)

Investor sentiment improves as stock rises 18%

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel

Investor sentiment improves as stock rises 17%

Consensus revenue estimates fall by 10%

Price target decreased by 11% to CN¥17.60

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) announces an Equity Buyback for CNY 100 million worth of its shares.

Consensus EPS estimates fall by 13%

Third quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.16 in 3Q 2022)

Price target decreased by 10% to CN¥20.63

Second quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.28 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.81 (vs CN¥0.34 in FY 2021)

Consensus EPS estimates increase by 11%

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.053 in 3Q 2021)

Price target increased to CN¥18.00

Second quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.17 in 2Q 2021)

Zhejiang Huahai Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1.56 billion in funding

Price target increased to CN¥15.50

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥0.34 (vs CN¥0.64 in FY 2020)

Price target increased to CN¥15.50

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.34 (vs CN¥0.64 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target increased to CN¥15.50

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.24 in 2Q 2020)

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) announces an Equity Buyback for CNY 200 million worth of its shares.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.15 in 1Q 2020)

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.64 (vs CN¥0.41 in FY 2019)

New 90-day low: CN¥28.88

Market bids up stock over the past week

Third quarter 2020 earnings released: EPS CN¥0.18

New 90-day low: CN¥31.49

Price target raised to CN¥12.27

Third quarter earnings released

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 20, 2020

Analysts update estimates

New 90-day low: CN¥31.92

First half earnings released

New 90-day high - CN¥44.83

New 90-day high - CN¥41.96

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi